Stocksigma LogoStocksigma Logo

Brooks Laboratories Approves Demerger of Manufacturing Business into Abridge Speciality

The Board of Brooks Laboratories approved the demerger of its Manufacturing Business into wholly owned subsidiary Abridge Speciality on 14th Oct'26

Brooks Laboratories Approves Demerger of Manufacturing Business into Abridge Speciality

Brooks Laboratories Ltd 路 Others (Uncategorized) 路 14 Oct 2026, 11:17 pm

Brooks Laboratories Approves Demerger of Manufacturing Business into Abridge Speciality The Board of Brooks Laboratories approved the demerger of its Manufacturing Business into wholly owned subsidiary Abridge Speciality on 14th Oct'26. The transferred unit contributed Rs. 8,287.26 lakhs in FY26, representing 96.66% of total revenue. Shareholders will receive 1 share of Abridge Speciality for every 1 share held in Brooks Laboratories, with identical shareholding mirror (52.62% promoter, 47.38% public). Post-demerger, Abridge Speciality will list on BSE and NSE and be renamed Brooks Laboratories, while the residual trading business will be renamed Xuri Lifesciences. Listing is targeted within ~16 months.

Original exchange filing (PDF)

More announcements from Brooks Laboratories Ltd

All Brooks Laboratories Ltd announcements